4-valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years

Pediatrics

Volumn 140, Issue 6, 2017, Pages

  Ferris, Daron G ^a   Samakoses, Rudiwilai ^b   Block, Stanley L ^c   Lazcano Ponce, Eduardo ^d   Restrepo, Jaime Alberto ^e   Mehlsen, Jesper ^f   Chatterjee, Archana ^g   Iversen, Ole Erik ^h   Joshi, Amita ⁱ   Chu, Jian Li ⁱ   Krick, Andrea Likos ⁱ   Saah, Alfred ⁱ   Das, Rituparna ⁱ  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^c Kentucky Pediatric Research Institute   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e Fundación Centro de Investigación Clínica   (Colombia)

^f FREDERIKSBERG HOSPITAL   (Denmark)

^g UNIVERSITY OF SOUTH DAKOTA   (United States)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOGENICITY; INFORMED CONSENT; MALE; NONHUMAN; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; VACCINATION; CHILD; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION;

ADOLESCENT; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 85037706473     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-3947     Document Type: Article

References (17)

1. Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine Gardasil. J Adolesc Health. 2011;49(5): 467-475
2. Block SL, Nolan T, Sattler C, et al; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5): 2135-2145
3. Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Lévesque LE. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5). Available at: www. pediatrics. org/ cgi/ content/ full/ 135/ 5/ e1131
4. Sull M, Eavey J, Papadouka V, Mandell R, Hansen MA, Zucker JR. Adolescent vaccine co-administration and coverage in New York City: 2007-2013. Pediatrics. 2014;134(6). Available at: www. pediatrics. org/ cgi/ content/ full/ 134/ 6/ e1576
5. Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2005. MMWR Surveill Summ. 2006;55(5): 1-108
6. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5): 325-339
7. Luna J, Plata M, Gonzalez M, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult women. PLoS One. 2013;8(12): e83431
8. Ferris D, Samakoses R, Block SL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3). Available at: www. pediatrics. org/ cgi/ content/ full/ 134/ 3/ e657
9. Reisinger KS, Block SL, Lazcano- Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3): 201-209
10. Brown DR, Garland SM, Ferris DG, et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin. 2011;7(2): 230-238
11. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagn Lab Immunol. 2003;10(1): 108-115
12. Villa LL, Perez G, Kjaer SK, et al; FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19): 1915-1927
13. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5): 401-411
14. Olsson S-E, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 viruslike particle (VLP) vaccine. Vaccine. 2007;25(26): 4931-4939
15. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised doubleblind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5): 271-278
16. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and lowgrade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23): 2995-3002
17. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8): 711-723